Aged Garlic Extract Inhibits Human Platelet Aggregation by Altering Intracellular Signaling and Platelet Shape Change

被引:30
作者
Rahman, Khalid [1 ]
Lowe, Gordon M. [1 ]
Smith, Sarah [1 ]
机构
[1] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool L3 5UX, Merseyside, England
关键词
garlic; platelet aggregation; GPIIb/Illa receptor; cAMP; fibrinogen; thrombosis; NITRIC-OXIDE; DIETARY SUPPLEMENTATION; BIOCHEMICAL-MECHANISMS; RECEPTOR; CGMP; ADP; PHOSPHODIESTERASES; INFLAMMATION; ACTIVATION; CAMP;
D O I
10.3945/jn.114.202408
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Increased platelet aggregation plays a pivotal role in the etiology of cardiovascular disease. Upon platelet aggregation, an increase in free cytoplasmic Ca2+ results in the inhibition of soluble guanylyl cyclase (sGC) and adenylyl cyclase (AC), leading to a decrease in cyclic guaninosine-5'-monophosphate (cGMP) and cAMP, respectively. This leads to the activation of the glycoprotein I lb/I I la (GPIlb/111a) fibrinogen receptor, resulting in platelet shape change. Aged garlic extract (AGE) decreases platelet aggregation; however, the mechanisms involved are not clearly defined. Objective: Our objective was to investigate the effects of AGE on intraplatelet cell signaling and platelet shape change. Methods: Platelets from 14 participants were studied. Platelet aggregation was induced by ADP in the presence of AGE up to a concentration of 6.25% (vol:vol) alone or in combination with 3-morpholinosydnonimine (Sin -1), a nitric oxide donor. The experiments with AGE were repeated in the presence of 3-isobuty1-1-methylxanthine (IBMX), a phosphodiesterase inhibitor. In a series of separate experiments, platelet aggregation was induced in the presence of either 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), an sGC inhibitor, or 9-(tetrahydro-2-furanyI)-9H-purin-6-amine (SQ22536), an AC inhibitor, or a combination of both in the presence of IBMX and AGE. Intraplatelet cGMP and cAMP were measured. The platelets were also subjected to scanning electron microscopic analysis, and their binding to fibrinogen was determined. Results: AGE decreased platelet aggregation at all concentrations tested; this decrease was more marked in the presence of Sin -1 and ranged between 15% and 67%. The presence of IBMX also led to a decrease (17-35%) in platelet aggregation at all AGE concentrations and a significant decrease in the amounts of cGMP (24-41%) and cAMP (19-70%), respectively, in the presence of ODQ and SQ22536. The presence of AGE significantly inhibited the binding of activated platelets to fibrinogen, preventing changes in platelet shape. Conclusion: These results indicate that AGE inhibits platelet aggregation by increasing cyclic nucleotides and inhibiting fibrinogen binding and platelet shape change.
引用
收藏
页码:410S / 415S
页数:6
相关论文
共 34 条
[1]   Aged garlic extract inhibits platelet activation by increasing intracellular cAMP and reducing the interaction of GPIIb/IIIa receptor with fibrinogen [J].
Allison, Gillian L. ;
Lowe, Gordon M. ;
Rahman, Khalid .
LIFE SCIENCES, 2012, 91 (25-26) :1275-1280
[2]   Effect of garlic on cardiovascular disorders: a review [J].
Banerjee, Sanjay K. ;
Maulik, Subir K. .
NUTRITION JOURNAL, 2002, 1 (1)
[3]   Platelets at work in primary hemostasis [J].
Broos, Katleen ;
Feys, Hendrik B. ;
De Meyer, Simon F. ;
Vanhoorelbeke, Karen ;
Deckmyn, Hans .
BLOOD REVIEWS, 2011, 25 (04) :155-167
[4]   A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations [J].
Crane, MS ;
Rossi, AG ;
Megson, IL .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (06) :849-859
[5]   Dietary supplementation with aged garlic extract reduces plasma and urine concentrations of 8-iso-prostaglandin F2α in smoking and nonsmoking men and women [J].
Dillon, SA ;
Lowe, GM ;
Billington, D ;
Rahman, K .
JOURNAL OF NUTRITION, 2002, 132 (02) :168-171
[6]   Antioxidant properties of aged garlic extract: an in vitro study incorporating human low density lipoprotein [J].
Dillon, SA ;
Burmi, RS ;
Lowe, GM ;
Billington, D ;
Rahman, K .
LIFE SCIENCES, 2003, 72 (14) :1583-1594
[7]   ORALLY-ACTIVE NONPEPTIDE FIBRINOGEN RECEPTOR (GPIIB/IIIA) ANTAGONISTS - IDENTIFICATION OF 4-[4-[4-(AMINOIMINOMETHYL)PHENYL]-1-PIPERAZINYL]-1-PIPERIDINEACETIC ACID AS A LONG-ACTING, BROAD-SPECTRUM ANTITHROMBOTIC AGENT [J].
ELDRED, CD ;
EVANS, B ;
HINDLEY, S ;
JUDKINS, BD ;
KELLY, HA ;
KITCHIN, J ;
LUMLEY, P ;
PORTER, B ;
ROSS, BC ;
SMITH, KJ ;
TAYLOR, NR ;
WHEATCROFT, JR .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (23) :3882-3885
[8]   Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3 [J].
Feijge, MAH ;
Ansink, K ;
Vanschoonbeek, K ;
Heemskerk, JWM .
BIOCHEMICAL PHARMACOLOGY, 2004, 67 (08) :1559-1567
[9]   SYNERGISTIC INTERACTION OF ADENYLATE-CYCLASE ACTIVATORS AND NITRIC-OXIDE DONOR SIN-1 ON PLATELET CYCLIC-AMP [J].
FISCH, A ;
MICHAELHEPP, J ;
MEYER, J ;
DARIUS, H .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 289 (03) :455-461
[10]   cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action [J].
Francis, Sharron H. ;
Busch, Jennifer L. ;
Corbin, Jackie D. .
PHARMACOLOGICAL REVIEWS, 2010, 62 (03) :525-563